Acceptability and Utilization of Newer Technologies and Effects on Glycemic Control in Type 2 Diabetes: Lessons Learned from Lockdown
Authors:
- Ranjit Mohan AnjanaRARanjit Mohan Anjana
- Rajendra PradeepaRPRajendra Pradeepa
- Mohan DeepaMDMohan Deepa
- Saravanan JebaraniSJSaravanan Jebarani
- Ulagamathesan VenkatesanUlagamathesan Venkatesan
- Somasundaram Jaya ParvathiSPSomasundaram Jaya Parvathi
- Muthuswamy BalasubramanyamMBMuthuswamy Balasubramanyam
- Venkatesan RadhaVRVenkatesan Radha
- Subramani PoongothaiSPSubramani Poongothai
- Vasudevan SudhaVSVasudevan Sudha
- Coimbatore Subramanian Shanthi RaniCRCoimbatore Subramanian Shanthi Rani
- Harish RanjaniHRHarish Ranjani
- 30 June 2020
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 22 (7) , 527-534
Abstract
Aim: To evaluate the effects of a prolonged lockdown due to Coronavirus (COVID-19) on the adoption of newer technologies and changes in glycemic control on patients with type 2 diabetes (T2D) in India. Methods: The study population included a random list of 3000 individuals with T2D derived from 30,748 individuals who had visited a large tertiary diabetes center during the past year. The survey was carried out through a telephonic interview. A structured questionnaire was used to collect information on changes in lifestyle, access and challenges to diabetes care and use of technologies such as telemedicine facilities and use of self-monitoring of blood glucose (SMBG), etc. Results: Of the 2510 individuals successfully interviewed (83.7% response rate), 382 (15.2%) reported having attempted to consult their health care providers during the lockdown, of whom only 30.6% utilized the telemedicine facility. However, 96 (82%) of those who utilized the telemedicine facility ( n = 117) were happy with their experience and 68 (58.1%) were willing to continue to use the facility in the future. Only 11.4% of participants utilized online support for management of diabetes. Use of SMBG increased significantly from 15.5% to 51.3% during the lockdown. There was an improvement in glycemic control during the lockdown (HbA1c:before vs. during lockdown: 8.2% ± 1.9% vs. 7.7% ± 1.7%, P < 0.001) in a nonrandomly selected subset of subjects ( n = 205). Conclusions: Acceptance of telemedicine facilities remains suboptimal in this Asian Indian population, in spite of high levels of satisfaction among those who utilized it. The COVID-19 pandemic and the subsequent lockdown have not adversely affected metabolic control in our patients, and indeed there appears to be an improvement in HbA1c levels. Greater accessibility and acceptance of technology could help individuals with diabetes to maintain better contact with their physicians and ensure better metabolic control in the future.Keywords
This publication has 8 references indexed in Scilit:
- Coping with diabetes during the COVID – 19 lockdown in India: Results of an online pilot surveyDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysisDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in ItalyDiabetes Therapy, 2020
- Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United StatesJournal of Diabetes Science and Technology, 2020
- Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 DiabetesCell Metabolism, 2020
- Clinical Effectiveness of Telemedicine in Diabetes Mellitus: A Meta-Analysis of 42 Randomized Controlled TrialsTelemedicine and e-Health, 2019
- Use of Telemedicine Technologies in Diabetes Prevention and Control in Resource-Constrained Settings: Lessons Learned from Emerging EconomiesDiabetes Technology & Therapeutics, 2019
- Evaluation of the clinical outcomes of telehealth for managing diabetesMedicine, 2018